San Giovanni Rotondo (FG), Italy Clinical Trials

A listing of San Giovanni Rotondo (FG), Italy clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
I am looking for
added new label for I am looking for
Advanced Filters
Found 63 clinical trials
International Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lymphoma

Primary objectives: Randomization R1, all patients eligible: To examine, whether the cumulative incidence of relapses with involvement of the CNS (CNS relapse, pCICR) can be decreased by a modified induction therapy including dexamethasone (experimental arm) instead of prednisone (standard arm) Randomization R2, only patients with high risk LBL eligible: to …

Dipartimento Biomedicina Et Evolutiva- U.O. Pediatrica I Policlinico
 (71.6 away) Contact site
  • 19 Jun, 2021
  • +223 other locations
GRAVITAS-309: Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease

The purpose of this study is to assess the efficacy and safety of itacitinib in combination with corticosteroids as first-line treatment for moderate or severe chronic graft-versus-host disease (cGVHD).

platelet count
neutrophil count
cell transplantation
A.O.U. Federico Ii
 (98.1 away) Contact site
  • 01 Aug, 2021
  • +159 other locations
Study of Durvalumab Given With Chemotherapy Durvalumab in Combination With Tremelimumab Given With Chemotherapy or Chemotherapy in Patients With Unresectable Urothelial Cancer

This is a randomized, open-label, controlled, multi-center, global Phase III study to determine the efficacy and safety of combining durvalumab tremelimumab with standard of care (SoC) chemotherapy (cisplatin + gemcitabine or carboplatin + gemcitabine doublet) followed by durvalumab monotherapy versus SoC alone as first-line chemotherapy in patients with histologically or …

Research Site
 (98.1 away) Contact site
  • 01 Aug, 2021
  • +281 other locations
Study to Determine the Efficacy of Uproleselan (GMI-1271) in Combination With Chemotherapy to Treat Relapsed/Refractory Acute Myeloid Leukemia

This study will evaluate the efficacy of uproleselan (GMI-1271), a specific E-selectin antagonist, in combination with chemotherapy to treat relapsed/refractory AML, compared to chemotherapy alone. The safety of uproleselan when given with chemotherapy will also be investigated in patients with relapsed/refractory AML

refractory acute myeloid leukemia (aml)
Fondazione Policlinico Tor Vergata, U.O.C. Ematologia
 (159.2 away) Contact site
  • 31 Jul, 2021
  • +69 other locations
Effect of EPA-FFA on Polypectomy in Familial Adenomatous Polyposis

2 Year randomised, double-blind, placebo-controlled, parallel group study to determine the safety and efficacy of EPA-FFA gastro resistant capsules in FAP.

eicosapentaenoic acid
rectal anastomosis
IRCCS de Bellis
 (93.5 away) Contact site
  • 26 Jul, 2021
  • +28 other locations
Daratumumab Retreatment in Participants With Multiple Myeloma Who Have Been Previously Treated With Daratumumab

The purpose of this study is to compare the efficacy (rate of very good partial response [VGPR] or better as best response as defined by the International Myeloma Working Group [IMWG] criteria) of daratumumab subcutaneous (Dara-SC) in combination with carfilzomib and dexamethasone (Kd) with the efficacy of Kd in participants …

progressive disease
maintenance therapy
Universita Degli Studi di Roma 'Tor Vergata'
 (159.2 away) Contact site
  • 22 Jul, 2021
  • +162 other locations
A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis

A double-blind placebo controlled randomized Phase 3 study to determine if 80 or 100 mg of MGL-3196 as compared with placebo resolves NASH on liver biopsy and prevents progression to cirrhosis and/or advanced liver disease

liver disease
hepatic fibrosis
Fondazione Policlinico Universitario Agostino Gemelli
 (166.4 away) Contact site
  • 17 Jul, 2021
  • +229 other locations
Durvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer (TOPAZ-1)

Durvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer (TOPAZ-1)

advanced biliary tract carcinoma
recurrent disease
Research Site
 (98.1 away) Contact site
  • 29 Jul, 2021
  • +163 other locations
Safety and Tolerability of M254 in Healthy Volunteers and Immune Thrombocytopenic Purpura (ITP) Patients

The purpose of this study is to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of M254 after administration of a single ascending dose and repeat doses in healthy volunteers and immune thrombocytopenic purpura (ITP) patients. The pharmacodynamics of the drug will be measured as platelet response in patients with ITP.

immune globulin
Momenta Investigational Site
 (56.0 away) Contact site
  • 02 Apr, 2021
  • +29 other locations
Assess the Anti-Tumor Activity and Safety of Odronextamab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Primary objective is to assess the anti-tumor activity of single agent odronextamab as measured by the objective response rate (ORR) according to the Lugano Classification of response in malignant lymphoma (Cheson, 2014) and as assessed by independent central review in each of the following B-cell non-Hodgkin lymphoma (B-NHL) subgroups: In …

follicular lymphoma
marginal zone lymphoma
refractory b-cell non-hodgkin lymphoma
b-cell lymphoma
Regeneron Study Site
 (168.2 away) Contact site
  • 01 Aug, 2021
  • +84 other locations